About Oncophenomics
Oncophenomics is a company based in Hyderabad (India) founded in 2016 by Mike Raghavan and Shibichakravarthy Kannan. Oncophenomics has raised $606.18 thousand across 5 funding rounds from investors including Pfizer, Mumbai Angels and T-Hub. Oncophenomics operates in a competitive market with competitors including Personalis, Geneoscopy, OncoDNA, Ultivue and Strata Oncology, among others.
- Headquarter Hyderabad, India
- Founders Mike Raghavan, Shibichakravarthy Kannan
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Theranosis Life Sciences Private Limited
- Date of Incorporation 05 Feb, 2016
- Jurisdiction Habsiguda, Telangana, India
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$606.18 K (USD)
in 5 rounds
-
Latest Funding Round
$81.51 K (USD), Grant
Sep 12, 2022
-
Investors
Pfizer
& 46 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Oncophenomics
Oncophenomics has successfully raised a total of $606.18K across 5 strategic funding rounds. The most recent funding activity was a Grant round of $81.51 thousand completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Oncophenomics
Oncophenomics has secured backing from 47 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Pfizer, Mumbai Angels and T-Hub.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sustainable startups are supported via innovation curation and venture funding.
|
Locked | Locked | Locked | |
|
Innovation hub connecting startups, corporates, and partners in technology and ecosystem development.
|
Locked | Locked | Locked | |
|
Early-stage venture investments are facilitated by Mumbai Angels network.
|
Locked | Locked | Locked |
Investor details for Oncophenomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oncophenomics
Investment portfolio details for Oncophenomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oncophenomics
Detailed financials for Oncophenomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncophenomics Comparisons
Peer comparison for Oncophenomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oncophenomics
Oncophenomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Personalis, Geneoscopy, OncoDNA, Ultivue and Strata Oncology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Non-invasive biomarker tests for colorectal cancer are developed.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Provider of test panels for personalized cancer therapies
|
|
| Locked | Locked | Locked |
Genetic sequencing is provided for late-stage cancer patients.
|
|
| Locked | Locked | Locked |
Immunotherapy platform is developed for personalized cancer treatment.
|
Detailed competitors of Oncophenomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncophenomics
Complete news archive for Oncophenomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oncophenomics
Oncophenomics was founded in 2016.
Oncophenomics is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Shibichakravarthy Kannan is the current CEO of Oncophenomics. They have also founded this company.
Oncophenomics is a funded company, having raised a total of $606.18K across 5 funding rounds to date.
Oncophenomics was founded in 2016 in Hyderabad, India, within the biotechnology sector. Genomic tests are developed to enable personalized medicine for cancer patients. The platform features Fathom Dx, a liquid biopsy test that integrates genomic and epigenomic biomarkers across the entire genome. This approach supports cancer diagnostics and informs clinical outcomes based on comprehensive biomarker analysis.
Oncophenomics's top competitors include Personalis, Geneoscopy and OncoDNA.
Oncophenomics has 47 investors. Key investors include Pfizer, Mumbai Angels, T-Hub, 50k Ventures, and Xseed Partners.
The valuation of Oncophenomics is $1.51M as of Mar 2018.